News • PhinC Development

PhinC launches SiMmAbs project

PhinC is conducting a research project to develop and validate innovative modeling methodologies applied to the specific development of monoclonal antibodies (mAbs).

Modeling & Simulation Strategies Must Be Integrated into Clinical Development

Read the interview of our President Bernard Orlandini, along with Marc Essodaigui, CEO of Active Biomarkers and Alexandre Durand-Salmon, CEO of Banook Group.

Blaise Pasquiers presents the mAbs project at PhinC

Translational PK/PD and Model-Informed Drug Development (MIDD) of monoclonal antibodies

PhinC joins French Tech

We are officially a member of the "La French Tech Paris-Saclay" community. An association that federates, creates connections and offers opportunities.